Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Despite the availability of numerous antiepileptic drugs, 20-30% of epileptic patients are pharmacoresistant with seizures not appropriately controlled. Consequently, new strategies to address this unmet medical need are required. T-type calcium channels play a key role in neuronal excitability and burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat various CNS disorders, in particular epilepsy. Herein we describe the identification of new 1,4-benzodiazepines as brain penetrant and selective triple T-type calcium channel blockers. From racemic hit 4, optimization work led to the preparation of pyridodiazepine 31c with improved physicochemical properties, solubility, and metabolic stability. The racemic mixture was separated by chiral preparative HPLC, and the resulting lead compound (3R,5S)-31c showed promising efficacy in the WAG/Rij-rat model of generalized nonconvulsive absence-like epilepsy.

[1]  J. Mosbacher,et al.  Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers. , 2016, Journal of medicinal chemistry.

[2]  E. Valjent,et al.  Blockade of T-type calcium channels prevents tonic-clonic seizures in a maximal electroshock seizure model , 2016, Neuropharmacology.

[3]  E. Perucca,et al.  Challenges in the clinical development of new antiepileptic drugs. , 2016, Pharmacological research.

[4]  M. Jarvis,et al.  Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639. , 2015, ACS medicinal chemistry letters.

[5]  M. Beller,et al.  Direct catalytic N-alkylation of amines with carboxylic acids. , 2014, Journal of the American Chemical Society.

[6]  T. Snutch,et al.  Low threshold T‐type calcium channels as targets for novel epilepsy treatments , 2014, British journal of clinical pharmacology.

[7]  Yurii S. Moroz,et al.  Bis(2,2,2-trifluoroethyl) carbonate as a condensing agent in one-pot parallel synthesis of unsymmetrical aliphatic ureas. , 2014, ACS combinatorial science.

[8]  A. Eschalier,et al.  T-type calcium channels in chronic pain: mouse models and specific blockers , 2014, Pflügers Archiv - European Journal of Physiology.

[9]  B. Kopecky,et al.  T-type calcium channel blockers as neuroprotective agents , 2014, Pflügers Archiv - European Journal of Physiology.

[10]  C. Tai,et al.  The T-type calcium channel as a new therapeutic target for Parkinson’s disease , 2014, Pflügers Archiv - European Journal of Physiology.

[11]  C. Yap,et al.  Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility , 2014, The Journal of physiology.

[12]  Hee-Sup Shin,et al.  T-type Ca2+ channels in absence epilepsy , 2014, Pflügers Archiv - European Journal of Physiology.

[13]  V. Crunelli,et al.  The many faces of T-type calcium channels , 2014, Pflügers Archiv - European Journal of Physiology.

[14]  Dieter Schmidt,et al.  New avenues for anti-epileptic drug discovery and development , 2013, Nature Reviews Drug Discovery.

[15]  G. Holmes,et al.  Development of new treatment approaches for epilepsy: Unmet needs and opportunities , 2013, Epilepsia.

[16]  Kee-Hyun Choi.  The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders , 2013, Expert opinion on drug discovery.

[17]  Hee-Sup Shin,et al.  T-type Ca2+ channels in normal and abnormal brain functions. , 2013, Physiological reviews.

[18]  J. Larner,et al.  Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells. , 2013, Biochemical pharmacology.

[19]  C. Lines,et al.  Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia , 2013, Human psychopharmacology.

[20]  T. Snutch,et al.  T-Type Calcium Channel Blockers That Attenuate Thalamic Burst Firing and Suppress Absence Seizures , 2012, Science Translational Medicine.

[21]  Steven V. Fox,et al.  Pyridyl amides as potent inhibitors of T-type calcium channels. , 2011, Bioorganic & medicinal chemistry letters.

[22]  Laurent Knerr,et al.  T-type calcium channels inhibitors: a patent review , 2011, Expert opinion on therapeutic patents.

[23]  S. Harbeson,et al.  Deuterium in Drug Discovery and Development , 2011 .

[24]  Steven V. Fox,et al.  Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. , 2010, ACS medicinal chemistry letters.

[25]  P. Lory,et al.  Role of voltage-gated calcium channels in epilepsy , 2010, Pflügers Archiv - European Journal of Physiology.

[26]  Yi Zhang,et al.  Genetic Enhancement of Thalamocortical Network Activity by Elevating α1G-Mediated Low-Voltage-Activated Calcium Current Induces Pure Absence Epilepsy , 2009, The Journal of Neuroscience.

[27]  Steven V. Fox,et al.  Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. , 2008, Journal of medicinal chemistry.

[28]  Steven V. Fox,et al.  Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. , 2008, Journal of medicinal chemistry.

[29]  Hee-Sup Shin,et al.  T-type Ca2+ channels as therapeutic targets in the nervous system. , 2008, Current opinion in pharmacology.

[30]  Naibo Yang,et al.  Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. , 2007, Assay and drug development technologies.

[31]  S. Remy,et al.  Molecular and cellular mechanisms of pharmacoresistance in epilepsy. , 2006, Brain : a journal of neurology.

[32]  Wei Zhu,et al.  Synthesis of aryl sulfones via L-proline-promoted CuI-catalyzed coupling reaction of aryl halides with sulfinic acid salts. , 2005, The Journal of organic chemistry.

[33]  Wei Zhu,et al.  Synthesis of aryl azides and vinyl azides via proline-promoted CuI-catalyzed coupling reactions. , 2004, Chemical communications.

[34]  E. van Luijtelaar,et al.  Genetic Animal Models for Absence Epilepsy: A Review of the WAG/Rij Strain of Rats , 2003, Behavior genetics.

[35]  E. Perez-Reyes.  Molecular physiology of low-voltage-activated t-type calcium channels. , 2003, Physiological reviews.

[36]  Daesoo Kim,et al.  Lack of the Burst Firing of Thalamocortical Relay Neurons and Resistance to Absence Seizures in Mice Lacking α1G T-Type Ca2+ Channels , 2001, Neuron.

[37]  Edmund M. Talley,et al.  Differential Distribution of Three Members of a Gene Family Encoding Low Voltage-Activated (T-Type) Calcium Channels , 1999, The Journal of Neuroscience.

[38]  D. R. Sutherland,et al.  A convenient method for cyanation of aromatic iodo compounds , 1994 .

[39]  J. Connor,et al.  Influence of substrate structure on copper(I)-assisted cyanide substitution in aryl halides , 1990 .

[40]  J. V. Braun,et al.  Fluoranthen und seine Derivate. III. Mitteilung , 1931 .

[41]  K. Rosenmund,et al.  Das am Ringkohlenstoff gebundene Halogen und sein Ersatz durch andere Substituenten. I. Mitteilung: Ersatz des Halogens durch die Carboxylgruppe , 1919 .